C Lee Ventola
About
In The Last Decade
C Lee Ventola
29 papers receiving 5.9k citations
Hit Papers
Peers
Comparison fields: 5 of 201
- Molecular Biology 1.3k
- Molecular Medicine 963
- Biomedical Engineering 919
- Applied Microbiology and Biotechnology 661
- Health 586
Countries citing papers authored by C Lee Ventola
This map shows the geographic impact of C Lee Ventola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Lee Ventola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Lee Ventola more than expected).
Fields of papers citing papers by C Lee Ventola
This network shows the impact of papers produced by C Lee Ventola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Lee Ventola. The network helps show where C Lee Ventola may publish in the future.
Co-authorship network of co-authors of C Lee Ventola
This figure shows the co-authorship network connecting the top 25 collaborators of C Lee Ventola. A scholar is included among the top collaborators of C Lee Ventola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Lee Ventola. C Lee Ventola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | Virtual Reality in Pharmacy: Opportunities for Clinical, Research, and Educational Applications. | 20 |
| 3 | 2 | |
| 4 | 15 | |
| 5 | Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations. | 76 |
| 6 | Immunization in the United States: Recommendations, Barriers, and Measures to Improve Compliance: Part 1: Childhood Vaccinations. | 111 |
| 7 | 9 | |
| 8 | 31 | |
| 9 | The antibiotic resistance crisis: part 1: causes and threats. breakdown → | 3544 |
| 10 | The antibiotic resistance crisis: part 2: management strategies and new agents. | 247 |
| 11 | Social media and health care professionals: benefits, risks, and best practices. breakdown → | 709 |
| 12 | Medical Applications for 3D Printing: Current and Projected Uses. breakdown → | 738 |
| 13 | Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants. | 48 |
| 14 | Biosimilars: part 2: potential concerns and challenges for p&t committees. | 11 |
| 15 | The nanomedicine revolution: part 2: current and future clinical applications. | 56 |
| 16 | The nanomedicine revolution: part 1: emerging concepts. | 92 |
| 17 | The drug shortage crisis in the United States: causes, impact, and management strategies. | 123 |
| 18 | "Où est mon andrologue ?" : le tabou masculin en santé sexuelle et reproductive | 1 |
| 19 | Current Issues Regarding Complementary and Alternative Medicine (CAM) in the United States: Part 3: Policies and Practices Regarding Dietary Supplements In Health Care Facilities. | 11 |
| 20 | Off-label drug information: regulation, distribution, evaluation, and related controversies. | 24 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.